(CIDRAP News) In a bird's eye view of pandemic H1N1 seroprevalence studies published so far, the World Health Organization (WHO) said today the reports consistently show older people had partial protection and that infection rates were higher in younger people, but it's too soon to estimate a global attack rate.
(CIDRAP News) A preliminary study from Germany suggests that an adjuvanted vaccine against the pandemic H1N1 virus was highly effective in adolescents and younger adults and moderately effective in older people, according to a report published yesterday in Eurosurveillance.
(CIDRAP News) European countries won't likely experience another wave of pandemic H1N1 influenza cases this spring and summer, though the virus will probably continue to circulate and be the region's dominant strain for the next flu season, the European Centre for Disease Prevention and Control (ECDC) said today.
(CIDRAP News) Just days before a Council of Europe hearing to discuss claims that pharmaceutical companies influenced the World Health Organization's (WHO's) pandemic response, the global body said charges by some European officials that the pandemic is "fake" are "wrong and irresponsible."
(CIDRAP News) Leading public health officials and experts have sharply rejected charges from some European officials that pharmaceutical companies used exaggerated claims about the H1N1 pandemic threat to scare governments into buying unnecessary stockpiles of vaccines.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
(CIDRAP News) With so much uncertainty over how broad and severe the next wave of H1N1 influenza could be, now is the time to focus on the two top goals of saving and sustaining lives, Dr. Julie Gerberding, former director of the US Centers for Disease Control and Prevention (CDC), told business groups today.
(CIDRAP News) The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.